Bone Therapeutics has developed two first-in-class products, ALLOB ® and PREOB ®, which target 3 bone indications in clinical trials and offer the potential for additional product extensions.
In addition, Bone Therapeutics is conducting preclinical research on next generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.